OpenBench
Private Company
Funding information not available
Overview
OpenBench operates a novel, fee-for-success business model in the AI-driven drug discovery space, leveraging its proprietary virtual screening platform to screen trillions of compounds. The company's technology focuses on finding potent, novel, and developable chemical matter for challenging targets, including allosteric sites and first-in-class proteins, with a reported 90% success rate on completed commercial projects. By requiring only a target structure and a primary assay, OpenBench provides a capital-efficient path for biotechs to launch discovery campaigns, transferring full IP ownership to the client upon project completion without royalties or milestones.
Technology Platform
AI-enabled structure-based virtual screening platform capable of screening trillions of compounds. Utilizes modeling (homology, MD, AlphaFold2) for targets lacking crystal structures and includes independent medicinal chemistry assessment to ensure hit quality, novelty, and developability.
Opportunities
Risk Factors
Competitive Landscape
OpenBench competes in the crowded AI-driven drug discovery space against public companies (e.g., Schrödinger, Recursion, Exscientia) and numerous private startups. Its primary differentiation is its strict 'fee-for-success' pricing, full IP transfer with no royalties, and focus on serving as a capital-efficient extension of biotech R&D teams rather than a traditional CRO or a drug developer.